Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
about
The great escape: viral strategies to counter BST-2/tetherinSpecies-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanismsBST-2/tetherin: a new component of the innate immune response to enveloped virusesAntiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteractionThe role of BST-2/Tetherin in host protection and disease manifestationConformational changes induced by a single amino acid substitution in thetrans-membrane domain of Vpu: Implications for HIV-1 susceptibility to channel blocking drugsTetherin/BST-2: Restriction Factor or Immunomodulator?Lack of adaptation to human tetherin in HIV-1 group O and P.HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variantsMutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.HIV protein sequence hotspots for crosstalk with host hub proteins.Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface.The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor?Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIVNef proteins from simian immunodeficiency viruses are tetherin antagonists.The role of BST2/tetherin in feline retrovirus infectionTetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogensAntibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells.Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral AntagonismHIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.Human cellular restriction factors that target HIV-1 replication.Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.Tetherin and its viral antagonists.Inhibition of budding/release of porcine endogenous retrovirus.Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.Anti-tetherin activities in Vpu-expressing primate lentiviruses.Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses.HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartmentAntagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
P2860
Q21090506-DCB717F0-7F28-4104-BA62-C42246C4059FQ21559418-A228BE12-0DA5-4052-AE54-6DC8BFE8E994Q24619066-0ABC3F6E-5D27-4467-9489-A1E5B4D756F4Q24630382-0C485FF2-B58F-49B9-A0CA-45D68E9287B7Q24635271-9A49A493-746B-4CDE-84CF-2F8F07489C5CQ26752737-D4A5A0BF-7C42-4BC3-A450-8DE6EB99EEE7Q27647751-97E3097A-0F51-4FCA-A20D-6AF13C7ABB9DQ30385433-86A4A734-5C3A-4C83-804E-3847E4140999Q30407564-A1E198AF-E7BF-4580-B164-20B6D3BFD107Q30815492-A0395A33-E1FD-4DB0-8519-A006670FF919Q33408799-653768D6-7C56-4E17-ADFD-23ED504B8703Q33450556-67B5EF8F-C01C-4FC1-9F46-8D0F40036B88Q33807551-66FF22D8-78C2-46A3-9055-556D8DA35C34Q33999393-BEEDFC76-6E12-4A1F-BC10-1B0D62030D32Q34476196-E4560827-3830-4E7F-B694-0D66DB503A21Q34492477-4047FE13-D62D-4F24-A9F3-18D112410BAAQ34505213-18BDD64A-5150-4EE2-8475-ACD76D307BBDQ34658653-8BC13942-B50D-4247-A6BA-C1986BD4BCF8Q34664616-B71111BA-B391-4E74-8852-E7A567005A48Q34819697-15E524F0-3FAB-4376-8236-9067FF8C1B43Q35383008-5CA9B141-0929-4319-A36B-AA8BA33B689AQ35531194-5FB7268A-A275-4EBE-82F4-4CD3B09DE35DQ35607295-DB6E6C4F-5EE6-4EE1-9186-703A5CB2F3EAQ35834559-980CE816-9F61-426B-9552-4DE3836B5DE1Q36371387-A692339C-739C-43AB-9F21-42AD44BEF3C9Q37115285-4F1A001B-A4D1-4A03-9019-1182D0979468Q37120188-EA54F50F-0B80-4068-8344-8593115AC832Q37378819-B6538FF5-8A1B-47E1-812F-4BA6112397D4Q37382519-FADC6AE8-1B87-4EDA-BE08-76FDA8D103B6Q37448301-7A8E26E0-F08E-4383-992C-FD9BDF207E0AQ37469794-B64A437A-8737-4E5F-820E-CAE705021F31Q37767654-DF7BE343-1D60-41DE-B355-ABF6280F1AF1Q37827428-7940EF99-F99F-4D6C-93D6-A358BE3AA412Q38984528-F7FAC605-9A70-41BB-A733-CE4C1F0A97F3Q39383826-CC5C29A3-C982-4D82-B58E-9A93FE3CCB8EQ39391944-01715FB2-F614-468C-BAEC-ECA88DD6A5F2Q39668496-2E0D7F3E-D544-4009-B7CF-48F75E5DF430Q39696123-01A8E6F6-5AEF-49AC-9ADA-56FB76FE1A21Q39801517-431F7ABC-797B-407B-AA7E-60D03454AD2FQ40051211-44EA7783-0819-4CBB-B788-DB81C7131CC8
P2860
Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Functional domains within the ...... d to enhance virus production.
@ast
Functional domains within the ...... d to enhance virus production.
@en
type
label
Functional domains within the ...... d to enhance virus production.
@ast
Functional domains within the ...... d to enhance virus production.
@en
prefLabel
Functional domains within the ...... d to enhance virus production.
@ast
Functional domains within the ...... d to enhance virus production.
@en
P2093
P2860
P1433
P1476
Functional domains within the ...... d to enhance virus production.
@en
P2093
Beth Noble
Paolo Abada
Paula M Cannon
P2860
P304
P356
10.1128/JVI.79.6.3627-3638.2005
P577
2005-03-01T00:00:00Z